glp-1 drugs in development What is the pipeline for future medications for obesity? Oral Small-Molecule GLP-1 Receptor Agonists:

Similar to our findings in the mouse model, the severity of human CL correlated with elevated eosinophils counts in the blood and in the skin lesions (Salaiza-Suazo et al, 2024)

Recent studies show GLP-1s may protect the kidneys and reduce the risk of heart problems and kidney failure in lupus patients Ankylosing Spondylitis, Sjgrens Syndrome, and Other Autoimmune Diseases These conditions share one thing: inflammation

This is compared to the more common form of glutathione GSH or reduced glutathione which quickly oxidises and disintegrates within minutes of being introduced to the body

Cagrilintide is still investigational in the U.S